S459
Clinical - Gynaecological
ESTRO 2026
Digital Poster 2797
Kragujevac. Kaplan–Meierand Long Rank test were applied to assess survival outcomes according to treatment timeliness. Results:
Benchmarking analysis of radiotherapy timeliness and impact on progression free survival in stage IIIC cervical cancer patients Marija Ž ivkovi ć Radojevi ć 1,2 , Katarina Jankovi ć 2,3 , Milo š Gruji ć 2,3 , Neda Milosavljevi ć 1,2 1 Clinical Oncology, University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia. 2 Center for Radiation Oncology, University Clinical Centre Kragujevac, Kragujevac, Serbia. 3 Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Purpose/Objective: Cervical cancer is the fourth most common tumor in women. Due to inadequate screening, poor preventive policy and low awareness of the importance of prevention, cervical cancer is predominantly diagnosed at a locally advanced stage in low and moderately developed countries. In these countries, limited resources significantly increase the time from diagnosis to initiation and completion of treatment, which can have a strong impact on long-term disease control. This study aimed to evaluate the impact of diagnosis-treatment timeline on three-year progression-free survival (PFS) in cervical cancer patients in FIGO IIIC1 and IIIC2 stages treated with definitive chemoradiation. Material/Methods: A retrospective clinical study based on the analysis of three-year PFS and impact of diagnosis-treatment timeline to disease progression in cervical cancer patients in FIGO IIIC1 and IIIC2 stages treated from January 2020 to January 2024 with external beam radiotherapy with simultaneous integrated or sequential boost doses, brachytherapy and chemopotentiation, according to thenational
One hundred and two patients were included (mean age 55.65±12.11 years), of which 70 were in stage IIIC1 and 32 in IIIC2 stage. Three years PFS was 57.8% with median 32.00±8.43 (range 15.46- 48.53) months. The influence of onset of symptoms-multidisciplinary tumor board (MDT) presentation, diagnosis-start of radiotherapy, onset of symptoms-end of radiotherapy treatment, MDT-end of radiotherapy, total duration of treatment up to 56 days on the time to disease progression was analyzed. The analysis showed that diagnosis - start of radiotherapy, onset of symptoms - end of radiotherapy, MDT - end of radiotherapy, and total treatment duration of up to 56 days affect three-year PFS to a statistically significant extent (p<0.05). Conclusion: In real-world clinical practice within a developing-country setting, timeliness of radiotherapy remains a major determinant of three-year PFS in FIGO IIIC stagecervical cancer patients. The total duration from diagnosis to initiation of radiotherapy exceeding 90 days, symptom onset to treatment completion exceeding 160 days, time from MDT presentation to end of radiotherapy exceeding 100 days and
protocol, at the Center for Radiation Oncology University Clinical Center
Made with FlippingBook - Share PDF online